Laboratory of Molecular Medicine, Department of Clinical Immunology Section 7631, Diagnostic Centre, Rigshospitalet, Ole Maaloesvej 26, DK-2200, Copenhagen N, Denmark.
Department of Neuroanaesthesiology, Neuroscience Centre, Rigshospitalet, Copenhagen, Denmark.
BMC Neurol. 2021 Apr 17;21(1):164. doi: 10.1186/s12883-021-02187-8.
Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease with great heterogeneity. Biological prognostic markers are needed for the patients to plan future supportive treatment, palliative treatment, and end-of-life decisions. In addition, prognostic markers are greatly needed for the randomization in clinical trials.
This study aimed to test the ALS Functional Rating Scale-Revised (ALSFRS-R) progression rate (ΔFS) as a prognostic marker of survival in a Danish ALS cohort.
The ALSFRS-R score at test date in association with duration of symptoms, from the onset of symptoms until test date, (defined as ΔFS') was calculated for 90 Danish patients diagnosed with either probable or definite sporadic ALS. Median survival time was then estimated from the onset of symptoms until primary endpoint (either death or tracheostomy). ΔFS' was subjected to survival analysis using Cox proportional hazards modelling, log-rank test, and Kaplan-Meier survival analysis.
Both ΔFS' and age was found to be strong predictors of survival of the Danish ALS cohort. Both variables are easily obtained at the time of diagnosis and could be used by clinicians and ALS patients to plan future supportive and palliative treatment. Furthermore, ΔFS', is a simple, prognostic marker that predicts survival in the early phase of disease as well as at later stages of the disease.
肌萎缩侧索硬化症(ALS)是一种具有高度异质性的进行性运动神经元疾病。需要生物预后标志物来帮助患者规划未来的支持治疗、姑息治疗和临终决策。此外,临床试验中的随机分组也非常需要预后标志物。
本研究旨在测试肌萎缩侧索硬化功能评定量表修订版(ALSFRS-R)进展率(ΔFS)作为丹麦 ALS 队列生存的预后标志物。
对 90 名丹麦患者(诊断为可能或明确的散发性 ALS)进行测试日期的 ALSFRS-R 评分与症状持续时间(从症状发作到测试日期,定义为ΔFS')相关联的分析。然后,从症状发作到主要终点(死亡或气管切开术)估计中位生存时间。使用 Cox 比例风险模型、对数秩检验和 Kaplan-Meier 生存分析对ΔFS'进行生存分析。
ΔFS'和年龄均被发现是丹麦 ALS 队列生存的强有力预测因素。这两个变量在诊断时很容易获得,可以由临床医生和 ALS 患者用于规划未来的支持和姑息治疗。此外,ΔFS'是一种简单的预后标志物,可预测疾病早期以及疾病晚期的生存情况。